157 related articles for article (PubMed ID: 23840879)
21. Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors.
Iwata-Kajihara T; Sumimoto H; Kawamura N; Ueda R; Takahashi T; Mizuguchi H; Miyagishi M; Takeda K; Kawakami Y
J Immunol; 2011 Jul; 187(1):27-36. PubMed ID: 21632716
[TBL] [Abstract][Full Text] [Related]
22. Tissue localization of tumor antigen-loaded mouse dendritic cells applied as an anti-tumor vaccine and their influence on immune response.
Rossowska J; Pajtasz-Piasecka E; Szyda A; Zietara N; Duś D
Folia Histochem Cytobiol; 2007; 45(4):349-55. PubMed ID: 18165174
[TBL] [Abstract][Full Text] [Related]
23. Clec9A
Gilfillan CB; Kuhn S; Baey C; Hyde EJ; Yang J; Ruedl C; Ronchese F
J Immunol; 2018 Apr; 200(8):2978-2986. PubMed ID: 29507107
[TBL] [Abstract][Full Text] [Related]
24. [Inhibiting effect of IL-10 in tumor microenvironment on anti-tumor activity of SOCS1-silenced DC vaccine].
Wang Z; You H; Song S
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Apr; 29(4):379-83. PubMed ID: 23643168
[TBL] [Abstract][Full Text] [Related]
25. Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo.
De Smedt T; Smith J; Baum P; Fanslow W; Butz E; Maliszewski C
J Immunol; 2002 Jan; 168(2):661-70. PubMed ID: 11777959
[TBL] [Abstract][Full Text] [Related]
26. Enhanced induction of anti-tumor immunity in human and mouse by dendritic cells pulsed with recombinant TAT fused human survivin protein.
Cho HI; Kim EK; Park SY; Lee SK; Hong YK; Kim TG
Cancer Lett; 2007 Dec; 258(2):189-98. PubMed ID: 17931768
[TBL] [Abstract][Full Text] [Related]
27. The role of the e3 ligase cbl-B in murine dendritic cells.
Wallner S; Lutz-Nicoladoni C; Tripp CH; Gastl G; Baier G; Penninger JM; Stoitzner P; Wolf D
PLoS One; 2013; 8(6):e65178. PubMed ID: 23762309
[TBL] [Abstract][Full Text] [Related]
28. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein.
Shimizu K; Thomas EK; Giedlin M; Mulé JJ
Cancer Res; 2001 Mar; 61(6):2618-24. PubMed ID: 11289139
[TBL] [Abstract][Full Text] [Related]
29. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
30. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour.
Song S; Zhang K; You H; Wang J; Wang Z; Yan C; Liu F
Clin Exp Immunol; 2010 Oct; 162(1):75-83. PubMed ID: 20735440
[TBL] [Abstract][Full Text] [Related]
31. Induction of efficient antitumor immunity using dendritic cells activated by recombinant Sendai virus and its modulation by exogenous IFN-beta gene.
Shibata S; Okano S; Yonemitsu Y; Onimaru M; Sata S; Nagata-Takeshita H; Inoue M; Zhu T; Hasegawa M; Moroi Y; Furue M; Sueishi K
J Immunol; 2006 Sep; 177(6):3564-76. PubMed ID: 16951315
[TBL] [Abstract][Full Text] [Related]
32. Enhanced priming of antigen-specific CTLs in vivo by embryonic stem cell-derived dendritic cells expressing chemokine along with antigenic protein: application to antitumor vaccination.
Matsuyoshi H; Senju S; Hirata S; Yoshitake Y; Uemura Y; Nishimura Y
J Immunol; 2004 Jan; 172(2):776-86. PubMed ID: 14707047
[TBL] [Abstract][Full Text] [Related]
33. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines.
Klein C; Bueler H; Mulligan RC
J Exp Med; 2000 May; 191(10):1699-708. PubMed ID: 10811863
[TBL] [Abstract][Full Text] [Related]
34. Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN-γ-dependent mechanism.
LaCasse CJ; Janikashvili N; Larmonier CB; Alizadeh D; Hanke N; Kartchner J; Situ E; Centuori S; Har-Noy M; Bonnotte B; Katsanis E; Larmonier N
J Immunol; 2011 Dec; 187(12):6310-7. PubMed ID: 22075702
[TBL] [Abstract][Full Text] [Related]
35. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses.
Weigel BJ; Panoskaltsis-Mortari A; Diers M; Garcia M; Lees C; Krieg AM; Chen W; Blazar BR
Exp Hematol; 2006 Oct; 34(10):1403-12. PubMed ID: 16982333
[TBL] [Abstract][Full Text] [Related]
36. The scavenger receptor MARCO mediates cytoskeleton rearrangements in dendritic cells and microglia.
Granucci F; Petralia F; Urbano M; Citterio S; Di Tota F; Santambrogio L; Ricciardi-Castagnoli P
Blood; 2003 Oct; 102(8):2940-7. PubMed ID: 12842997
[TBL] [Abstract][Full Text] [Related]
37. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
38. Cytostatic murine B16 cell-pulsed dendritic cells induce effective protection against melanoma in mice.
Joseph-Pietras D; Carlier A; Madoulet C; Albert P
Anticancer Res; 2007; 27(6B):3865-74. PubMed ID: 18225544
[TBL] [Abstract][Full Text] [Related]
39. Cell-permeable transgelin-2 as a potent therapeutic for dendritic cell-based cancer immunotherapy.
Kim HR; Park JS; Park JH; Yasmin F; Kim CH; Oh SK; Chung IJ; Jun CD
J Hematol Oncol; 2021 Mar; 14(1):43. PubMed ID: 33731208
[TBL] [Abstract][Full Text] [Related]
40. Tumor ablation plus co-administration of CpG and saponin adjuvants affects IL-1 production and multifunctional T cell numbers in tumor draining lymph nodes.
Raaijmakers TK; van den Bijgaart RJE; den Brok MH; Wassink M; de Graaf A; Wagenaars JA; Nierkens S; Ansems M; Scheffer GJ; Adema GJ
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
